Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.

    Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS
                   Pharmaceuticals Inc., and InterMune Inc.

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

LONDON, September 12, 2013

LONDON, September 12, 2013 /PRNewswire/ --

The U.S. equity market ended on a mixed note on Wednesday, September 11, 2013.
The S&P 500 and the Dow Jones Industrial Average gained 0.31% and 0.89%,
respectively, while the NASDAQ Composite fell by 0.11%. Shares in the
biotechnology industry ended lower, even as the broader market finished on a
mixed note. The major movers included Gilead Sciences Inc. (NASDAQ: GILD),
Halozyme Therapeutics Inc. (NASDAQ: HALO), NPS Pharmaceuticals Inc. (NASDAQ:
NPSP), and InterMune Inc. (NASDAQ: ITMN). AAAResearchReports.com free coverage
on GILD, HALO, NPSP, and ITMN is available upon registration at:

http://www.aaaresearchreports.com/register/ 

Shares in Gilead Sciences Inc. ended slightly higher on Wednesday, extending
their gains from previous trading sessions. The company's shares ended the day
0.11% higher at $62.93 after oscillating between $62.18 and $63.30. A total of
5.46 million shares were traded, which is below the daily average volume of
8.45 million. The company's stock has rallied 20.00% in the last three months
and 6.28% in the last one month, compared to a gain 3.87% and a loss of 0.14%
in the S&P 500 during the respective periods. Further, Gilead Sciences Inc.'s
stock is trading above its 50-day and 200-day moving averages of $58.82 and
$48.77, respectively. Download free technical research on GILD by signing up
at:

http://www.AAAResearchReports.com/GILD091213.pdf

Halozyme Therapeutics Inc.'s shares fell sharply on Wednesday, even as the
broader market ended on a mixed note. The company's shares ended the day at
$9.13, which is 1.19% lower than the previous day's price of $9.24. The
company's shares fluctuated between $8.90 and $9.32 during the trading
session. A total of 1.04 million shares were traded, which is below the daily
average volume of 1.55 million. Despite the sharp decline on Wednesday, the
company's shares have rallied 37.50% in the last three months and 35.86% in
the last one month, outperforming the S&P 500 which has gained 2.05% and lost
0.14% during the respective periods. Moreover, Halozyme Therapeutics Inc.'s
stock is trading above its 50-day and 200-day moving averages and close to its
52-week high of $9.45. Register now and get access to free analysis on HALO
at:

http://www.AAAResearchReports.com/HALO091213.pdf

Shares in NPS Pharmaceuticals Inc. plummeted on Wednesday, even as the broader
market finished the day on a mixed note. The company's shares oscillated
between $27.94 and $29.33 before finishing the day 4.50% lower at $28.20. A
total of 3.31 million shares were traded, which is above the daily average
volume of 1.48 million. Despite Wednesday's pullback, NPS Pharmaceuticals
Inc.'s shares have rallied 79.85% in the last three months and 24.28% in the
last one month, compared with a gain of 3.87% and a loss of 0.14% in the
S&P500 during the respective periods. Furthermore, NPS Pharmaceuticals Inc.'s
stock is trading above its 50-day and 200-day moving averages as well as close
to its 52-week high of $29.53. Sign up and read our complimentary report on
NPSP at:

http://www.AAAResearchReports.com/NPSP091213.pdf

Shares in InterMune Inc. fell sharply on Wednesday ending the day at $14.96,
which is 2.67% lower than the previous day's closing price of $15.37. The
company's shares oscillated between $14.84 and $15.37 during the trading
session. A total of 0.74 million shares were traded, which is below the daily
average volume of 1.32 million. InterMune Inc.'s shares have rallied 53.59% in
the last three months, outperforming the S&P 500 which has gained 3.87% during
the same period. Moreover, InterMune Inc's stock is trading above its 50-day
and 200-day moving averages of $13.74 and $10.58, respectively. The free
report on ITMN can be downloaded by signing up now at:

http://www.AAAResearchReports.com/ITMN091213.pdf

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

www.AAAresearchreports.com

SOURCE AAA Research Reports

Contact: Phone #: +1(646)396-9126 Contact Name: Peter F. Jones
info@aaaresearchreports.com
 
Press spacebar to pause and continue. Press esc to stop.